
    
      This is a single center, three-period, complete crossover, double-blind, randomised, placebo-
      and active-controlled study to compare the preliminary efficacy of a single dose of SR419 to
      placebo and active control in patients with peripheral neuropathic pain. The study also aims
      to evaluate the safety, tolerability, and PK of single doses of SR419 in patients with
      peripheral neuropathic pain.
    
  